Clinical syndromes of alcoholic liver disease

Digestive Diseases

Volumn 23, Issue 3-4, 2006, Pages 255-263

  Adachi, Masayuki ^a   Brenner, David A ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Alcoholic liver disease; Fibrosis; Steatohepatitis; Steatosis

Indexed keywords

ACETALDEHYDE; ADIPONECTIN; ALCOHOL; BIOLOGICAL MARKER; CYTOKINE; PENTOXIFYLLINE; PREDNISOLONE; REACTIVE OXYGEN METABOLITE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; CYTOKINE PRODUCTION; HUMAN; LABORATORY TEST; LIVER FIBROSIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ALCOHOLISM; BIOPSY, NEEDLE; DISEASE PROGRESSION; ETHANOL; FATTY LIVER, ALCOHOLIC; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 33644652173     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090173     Document Type: Article

References (82)

1. Mann RE, Smart RG, Govoni R: The epidemiology of alcoholic liver disease. Alcohol Res Health 2003;27:209-219.
2. Mandayam S, Jamal MM, Morgan TR: Epidemiology of alcoholic liver disease. Semin Liver Dis 2004;24:217-232.
3. Day CP: Who gets alcoholic liver disease: nature or nurture? J R Coll Physicians Lond 2000;34:557-562.
4. Reeves HL, Burt AD, Wood S, Day CP: Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996;25:677-683.
5. Worner TM, Lieber CS: Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985;254:627-630.
6. Talley NJ, Roth A, Woods J, Hench V: Diagnostic value of liver biopsy in alcoholic liver disease. J Clin Gastroenterol 1988;10:647-650.
7. MacSween RN, Burt AD: Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986;6:221-232.
8. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P: Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984;ii:241-244.
9. Teli MR, Day CP, Burt AD, Bennett MK, James OF: Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987-990.
10. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP: The continuing epidemic of obesity in the United States. JAMA 2000;284:1650-1651.
11. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
12. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000;132:112-117.
13. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S: Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35: 635-638.
14. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC: Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-111.
15. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, Becker U, Bendtsen F: Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-755.
16. Alexander JF, Lischner MW, Galambos JT: Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 1971;56:515-525.
17. Bird GL, Williams R: Factors determining cirrhosis in alcoholic liver disease. Mol Aspects Med 1988;10:97-105.
18. Diehl AM: Alcoholic liver disease: natural history. Liver Transpl Surg 1997;3:206-211.
19. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T: Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847-1853.
20. Galambos JT: Alcoholic hepatitis: its therapy and prognosis. Prog Liver Dis 1972;4:567-588.
21. Pares A, Caballeria J, Bruguera M, Torres M, Rodes J: Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2:33-42.
22. Morgan MY: The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl 1994;2:335-343.
23. Poynard T, Naveau S, Doffoel M, Boudjema K, Vanlemmens C, Mantion G, Messner M, Launois B, Samuel D, Cherqui D, Pageaux G, Bernard PH, Calmus Y, Zarski JP, Miguet JP, Chaput JC: Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. J Hepatol 1999;30:1130-1137.
24. Burra P, Lucey MR: Liver transplantation in alcoholic patients. Transpl Int 2005;18:491-498.
25. Starzl TE, Van Thiel D, Tzakis AG, Iwatsuki S, Todo S, Marsh JW, Koneru B, Staschak S, Stieber A, Gordon RD: Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 1988;260:2542-2544.
26. Lucey MR, Merion RM, Henley KS, Campbell DA Jr, Turcotte JG, Nostrant TT, Blow FC, Beresford TP: Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology 1992;102:1736-1741.
27. National Institutes of Health Consensus Development Conference Statement: liver transplantation - June 20-23, 1983. Hepatology 1984;4(suppl):107S-110S.
28. Anantharaju A, Van Thiel DH: Liver transplantation for alcoholic liver disease. Alcohol Res Health 2003;27:257-268.
29. Lieber CS, Jones DP, Decarli LM: Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965;44:1009-1021.
30. Salaspuro MP, Shaw S, Jayatilleke E, Ross WA, Lieber CS: Attenuation of the ethanol-induced hepatic redox change after chronic alcohol consumption in baboons: metabolic consequences in vivo and in vitro. Hepatology 1981;1:33-38.
31. You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW: The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004;127:1798-1808.
32. You M, Fischer M, Deeg MA, Crabb DW: Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002;277:29342-29347.
33. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T: Peroxisome proliferator-activated receptor alpha-isofbrm deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998;273:29577-29585.
34. Fischer M, You M, Matsumoto M, Crabb DW: Peroxisome proliferator- activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003;278:27997-28004.
35. Day CP, James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998;114:842-845.
36. Thurman RG, Bradford BU, Iimuro Y, Frankenberg MV, Knecht KT, Connor HD, Adachi Y, Wall C, Arteel GE, Raleigh JA, Forman DT, Mason RP: Mechanisms of alcohol-induced hepatotoxicity: studies in rats. Front Biosci 1999;4:e42-e46.
37. Fukui H, Brauner B, Bode JC, Bode C: Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991;12:162-169.
38. Thurman RG: II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998;275:G605-G611.
39. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218-224.
40. Nanji AA, Khettry U, Sadrzadeh SM: Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994;205:243-247.
41. Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gabele E, Isayama F, Thurman RG: Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002;168:2963-2969.
42. Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, Thurman RG: Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 2001;166:4737-4742.
43. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG: Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001;34:101-108.
44. McClain CJ, Shedlofsky S, Barve S, Hill DB: Cytokines and alcoholic liver disease. Alcohol Health Res World 1997;21:317-320.
45. McClain CJ, Cohen DA: Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-351.
46. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG: Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26:1530-1537.
47. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG: Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952.
48. Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N: Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology 2002;123:291-300.
49. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS: Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
50. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL: Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-259.
51. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-1648.
52. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R: Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-425.
53. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broet P, Emilie D: A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-1397.
54. Wu D, Cederbaum AI: Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003;27:277-284.
55. Adachi M, Ishii H: Role of mitochondria in alcoholic liver injury. Free Radic Biol Med 2002;32:487-491.
56. Caro AA, Cederbaum AI: Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 2004;44:27-42.
57. Arteel GE: Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003;124:778-790.
58. Kono H, Rusyn I, Yin M, Gabele E, Yamashina S, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM, Thurman RG: NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000;106:867-872.
59. McKim SE, Gabele E, Isayama F, Lambert JC, Tucker LM, Wheeler MD, Connor HD, Mason RP, Doll MA, Hein DW, Arteel GE: Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 2003;125:1834-1844.
60. Niemela O, Parkkila S, Yla-Herttuala S, Villanueva J, Ruebner B, Halsted CH: Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995;22:1208-1214.
61. Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P: In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997;26:135-142.
62. Niemela O, Juvonen T, Parkkila S: Immunohistochemical demonstration of acetaldehyde-modified epitopes in human liver after alcohol consumption. J Clin Invest 1991;87:1367-1374.
63. Holstege A, Bedossa P, Poynard T, Kollinger M, Chaput JC, Houglum K, Chojkier M: Acetaldehyde-modified epitopes in liver biopsy specimens of alcoholic and nonalcoholic patients: localization and association with progression of liver fibrosis. Hepatology 1994;19:367-374.
64. Israel Y, Hurwitz E, Niemela O, Arnon R: Monoclonal and polyclonal antibodies against acetaldehyde-containing epitopes in acetaldehyde-protein adducts. Proc Natl Acad Sci USA 1986;83:7923-7927.
65. Viitala K, Israel Y, Blake JE, Niemela O: Serum IgA, IgG, and IgM antibodies directed against acetaldehyde-derived epitopes: relationship to liver disease severity and alcohol consumption. Hepatology 1997;25:1418-1424.
66. Viitala K, Makkonen K, Israel Y, Lehtimaki T, Jaakkola O, Koivula T, Blake JE, Niemela O: Autoimmune responses against oxidant stress and acetaldehyde-derived epitopes in human alcohol consumers. Alcohol Clin Exp Res 2000;24:1103-1109.
67. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K: Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-566.
68. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
69. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737.
70. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
71. Eng FJ, Friedman SL: Fibrogenesis. I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000;279:G7-G11.
72. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005;115:209-218.
73. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793-d807.
74. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA: The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001;34:89-100.
75. Nieto N, Friedman SL, Greenwel P, Cederbaum AI: CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999;30:987-996.
76. Svegliati-Baroni G, Saccomanno S, van Goor H, Jansen P, Benedetti A, Moshage H: Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001;21:1-12.
77. Gressner AM: Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 1995;22(suppl):28-36.
78. Whalen R, Rockey DC, Friedman SL, Boyer TD: Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress. Hepatology 1999;30:927-933.
79. Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, Foschi M, Caligiuri A, Pinzani M, Surrenti C: Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997;25:361-367.
80. Moshage H, Casini A, Lieber CS: Acetaldehyde selectively stimulates collagen production in cultured rat liver fat-storing cells but not in hepatocytes. Hepatology 1990;12:511-518.
81. Casini A, Cunningham M, Rojkind M, Lieber CS: Acetaldehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism. Hepatology 1991;13:758-765.
82. Brenner DA, Chojkier M: Acetaldehyde increases collagen gene transcription in cultured human fibroblasts. J Biol Chem 1987;262:17690-17695.